CSPC Group announced on September 16 that the phase II clinical trial of the SYH2069 injection developed by the group to treat adult type 2 diabetes has officially started at the first research center in China. This product is a novel fatty acid-modified polypeptide long-acting glucagon-like peptide-1 receptor and a glucose-dependent insulin-promoting polypeptide receptor dual-target bi-biased agonist. It is designed to selectively activate GLP-1R and GIPR to promote insulin secretion in a glucose-dependent manner. It is expected to work collaboratively to lower sugar and lose weight by suppressing appetite, delaying gastric emptying, increasing satiety, and reducing caloric intake.

CSPC Group announced on September 16 that the phase II clinical trial of the SYH2069 injection developed by the group to treat adult type 2 diabetes has officially started at the first research center in China. This product is a novel fatty acid-modified polypeptide long-acting glucagon-like peptide-1 receptor and a glucose-dependent insulin-promoting polypeptide receptor dual-target bi-biased agonist. It is designed to selectively activate GLP-1R and GIPR to promote insulin secretion in a glucose-dependent manner. It is expected to work collaboratively to lower sugar and lose weight by suppressing appetite, delaying gastric emptying, increasing satiety, and reducing caloric intake.